Celgene Corporation (CELG) : The total money flow in Celgene Corporation (CELG) was negative ($4.24 million), showing the domination of sellers in the Monday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $50.07 million. Transactions on upticks were comparatively lower at $45.84 million. The uptick to downtick ratio was 0.92. The total block trades done on upticks were valued at $1.39 million. The total block trades on downticks were valued at $3.13 million. The uptick to the downtick ratio of block trades was 0.44. The money flow during block trades was negative ($1.74 million) when the stock traded with a gain of $2 cent. Celgene Corporation (CELG) was $102.87, an increase of 0.02% over the previous days close.
Celgene Corporation has dropped 4.77% during the last 3-month period . Year-to-Date the stock performance stands at -14.25%. Celgene Corporation has dropped 0.69% in the last five trading days, however, the shares have posted positive gains of 2.46% in the last 4 weeks. In a related news, Hugin Robert J, director officer (see remarks) of Celgene Corp /De/, unloaded 75,000 shares at an average price of $100.16 on June 20, 2016. The total amount of the transaction was worth $7,512,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Celgene Corporation (NASDAQ:CELG): On Mondays trading session , Opening price of the stock was $102.85 with an intraday high of $103.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $102.01. However, the stock managed to close at $102.7, a loss of 0.15% for the day. On the previous day, the stock had closed at $102.85. The total traded volume of the day was 2,530,186 shares.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.